OptimizeRx’s Angelo Campano Named to MM+M 40 Under 40 List
February 23 2021 - 6:31AM
OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of
digital health solutions for life science companies, physicians and
patients, announced its senior vice president and principal of
agency channels, Angelo Campano, has been named to MM+M’s 2021 ‘40
Under 40’ list for his accomplishments and contributions to the
healthcare marketing industry.
The 40 Under 40 list shines a light on the young marketers whose
leadership, thinking and digital know-how have contributed to the
industry’s continued growth under challenging market conditions.
The list includes individuals ranging from pharma and biotech
companies, medical marketing agencies, device manufacturers,
analytics firms and health media.
The award is sponsored by MM+M, the media-of-record for
pharmaceutical marketing and commercialization delivering the most
balanced and relevant coverage of its subject matter.
Campano has more than 18 years of experience leading digital
channel partnerships and innovation. He has been an innovator
and leader in electronic health record (EHR) workflow and hub
services. Over the course of his career, he has established
partnerships with more than 245 EHR platforms, 100 specialty pharma
partners and five communications partners to bring life sciences
resources to more places at the point-of-care. Campano received
PM360’s ELITE Innovator Award in 2017 and was inducted into the
Medical Advertising Hall of Fame in 2014.
“As an industry trailblazer, Angelo has dedicated his career to
bringing innovation to the point-of-care,” said OptimizeRx chief
commercial officer, Steve Silvestro. “This award reflects the
tremendous positive impact he has had on our industry and the
companies he has served. We’re fortunate to have an industry leader
of Angelo’s caliber on our team.”
MM+M’s GM and editor-in-chief, Steve Madden, commented: “When we
started the 40 Under 40 program last year, we were blown away by
the volume of smart young people doing high-caliber work. As they
assume greater leadership roles, the industry should feel very
secure about its fortunes in the years ahead.”
See the full list of honorees at www.mmm40under40.com/home.
MM+M will celebrate the 2021 honorees during a virtual event
scheduled for March 25, 2021.
About MM+MFirst published in 1966 as Medical
Marketing & Media, MM+M is the media brand of record for
pharmaceutical marketing and commercialization, delivering the most
balanced and relevant coverage of the growing industry. The title
produces an essential mix of online breaking news and analysis
combined with monthly print features — timely, objective, original
editorial content for an executive audience of leaders and thinkers
who work in pharma, medical device, diagnostics and greater
healthcare marketing. MM+M also develops conferences and live and
virtual events, and engineers the industry’s premier awards
program, the MM+M Awards.
About OptimizeRxOptimizeRx is a digital health
company that provides communications solutions for life science
companies, physicians and patients. Connecting over half of
healthcare providers in the U.S. and millions of patients through a
proprietary network, the OptimizeRx digital health platform helps
patients afford and stay on medications. The platform unlocks new
patient and physician touchpoints for life science companies along
the patient journey, from point-of-care, to retail pharmacy,
through mobile patient engagement.
For more information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
OptimizeRx Contact Doug Baker, CFOTel
(248) 651-6568 (x807)dbaker@optimizerx.com
Media Relations Contact Maira Alejandra,
Media Relations ManagerTel (754)
245-7070 malejandra@optimizerx.com
Investor Relations Contact Ron Both,
CMA Tel (949) 432-7557 Email Contact
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Apr 2024 to May 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From May 2023 to May 2024